Can We Improve How We Treat Patients With Heart Failure in the Emergency Department?

Annals of Emergency Medicine

Volumn 51, Issue 5, 2008, Pages 583-584

  Diercks, Deborah B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIURETIC AGENT; GLYCERYL TRINITRATE; NESIRITIDE; NITROPRUSSIDE SODIUM;

CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG USE; EDITORIAL; EMERGENCY CARE; EMERGENCY WARD; HEALTH CARE QUALITY; HEART FAILURE; HOSPITALIZATION; HUMAN; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SYMPTOM; TREATMENT OUTCOME;

EMERGENCY SERVICE, HOSPITAL; HEART FAILURE; HUMANS; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE;

EID: 43049137971     PISSN: 01960644     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annemergmed.2008.01.321     Document Type: Editorial

References (12)

1. Miller A., Nazeer S., Pepe P., et al. Acutely decompensated heart failure in a county emergency department: a double-blind randomized controlled comparison of nesiritide vs. placebo treatment. Ann Emerg Med 51 (2008) 571-578
2. Rame J.E., Sheffield M.A., Dries D.L., et al. Outcomes after emergency department discharge with a primary diagnosis of heart failure. Am Heart J 142 (2001) 714-719
3. Cuffe M.S., Califf R.M., Adams Jr. K.F., et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 287 (2002) 1541-1547
4. Mebazaa A., Nieminen M.S., Packer M., et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 297 (2007) 1883-1891
5. O'Connor C.M., Gattis W.A., Adams Jr. K.F., et al. Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). J Am Coll Cardiol 41 (2003) 1452-1457
6. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 287 (2002) 1531-1540
7. Udelson J.E., McGrew F.A., Flores E., et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol 49 (2007) 2151-2159
8. Peacock W.F., Holland R., Gyarmathy R., et al. Observation unit treatment of heart failure with nesiritide: results from the Proaction Trial. J Emerg Med 29 (2005) 243-252
9. Gheorghiade M., Konstam M.A., Burnett Jr. J.C., et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 297 (2007) 1332-1343
10. Heart Failure Society of American. HFSA 2006 comprehensive heart failure practice guideline. J Card Fail 12 (2006) e1-e2
11. Teerlink J.R. Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure. Am Heart J 145 2 suppl (2003) S26-S33
12. Gheorghiade M., Adams Jr. K.F., Gattis W.A., et al. Surrogate end points in heart failure trials. Am Heart J 145 2 suppl (2003) S67-S70